This is an interesting topic indeed that has attracted much attention recently, especially for its link with precision medicine. (see the meeting on Precision Medicine of rare genetic syndromes_Still online:http://www.filadelfia.dk/filadelfia /aktuelt/nyheder/2019/12/05/international-konference).
Since more than20 years is known that the gene MeCP2 is electively expressed in the prefrontal cortex, playing an important role for neuronal maintenance, both in mice and in primates (1). The reduced expression of MeCP2 leads to functional hypo-connectivity in the medial prefrontal cortex that likely is the substrate for pervasive/behavioral and motor dysfunctions of Rett syndrome (2).
Only recently emerged that stimulating neurons in the medial prefrontal cortex can reverse symptoms in mice models of Rett syndrome (3). This suggests the possibility of targeted therapy for breathing, cognitive and behavioral dysfunctions in Rett patients, giving hope for precision medicine of this syndrome.